XML 53 R45.htm IDEA: XBRL DOCUMENT
v3.25.3

Segment Reporting (Tables) | 12 Months Ended
--- | ---
Jun. 30, 2025
Statements [Line Items] |
Disclosure of Operating Segment Information |
Operating segment information June 30, 2025 |  | Immunotherapy A$ |  |  | Unallocated A$ |  |  | Consolidated A$ |
Revenue |  |  |  |  |  |  |  |  |  |  |  |
License revenue |  |  | — |  |  |  | — |  |  |  | — |
Other income |  |  |  |  |  |  |  |  |  |  |  |
Research material sales |  |  | 59,709 |  |  |  | — |  |  |  | 59,709 |
Grant income |  |  | 4,974,823 |  |  |  | — |  |  |  | 4,974,823 |
Miscellaneous income |  |  | — |  |  |  | 390 |  |  |  | 390 |
Net change on fair value movement |  |  | — |  |  |  | 9,242 |  |  |  | 9,242 |
Interest income |  |  | — |  |  |  | 5,287,209 |  |  |  | 5,287,209 |
Total revenue and other income |  |  | 5,034,532 |  |  |  | 5,296,841 |  |  |  | 10,331,373 |
Result |  |  |  |  |  |  |  |  |  |  |  |
Segment Result |  |  | (65,020,504 | ) |  |  | 3,586,339 |  |  |  | (61,434,165 | )
Profit/(loss) before income tax expense |  |  | (65,020,504 | ) |  |  | 3,586,339 |  |  |  | (61,434,165 | )
Income tax expense |  |  | — |  |  |  | — |  |  |  | — |
Loss after income tax expense |  |  |  |  |  |  |  |  |  |  | (61,434,165 | )
Total segment assets |  |  | 156,983,434 |  |  |  | — |  |  |  | 156,983,434 |
Total segment liabilities |  |  | 13,348,071 |  |  |  | — |  |  |  | 13,348,071 |
Operating segment information June 30, 2024 |  | Immunotherapy A$ |  |  | Unallocated A$ |  |  | Consolidated A$ |
Revenue |  |  |  |  |  |  |  |  |  |  |  |
License revenue |  |  | — |  |  |  | — |  |  |  | — |
Other income |  |  |  |  |  |  |  |  |  |  |  |
Research material sales |  |  | 119,089 |  |  |  | — |  |  |  | 119,089 |
Grant income |  |  | 3,722,788 |  |  |  | — |  |  |  | 3,722,788 |
Net gain on fair value movement of warrants |  |  | — |  |  |  | — |  |  |  | — |
Net gain on foreign exchange |  |  | — |  |  |  | 113,458 |  |  |  | 113,458 |
Interest income |  |  | — |  |  |  | 3,882,757 |  |  |  | 3,882,757 |
Total revenue and other income |  |  | 3,841,877 |  |  |  | 3,996,215 |  |  |  | 7,838,092 |
Result |  |  |  |  |  |  |  |  |  |  |  |
Segment Result |  |  | (46,556,929 | ) |  |  | 3,840,304 |  |  |  | (42,716,625 | )
Profit/(loss) before income tax expense |  |  | (46,556,929 | ) |  |  | 3,840,304 |  |  |  | (42,716,625 | )
Income tax expense |  |  | — |  |  |  | — |  |  |  | — |
Loss after income tax expense |  |  |  |  |  |  |  |  |  |  | (42,716,625 | )
Total segment assets |  |  | 201,579,281 |  |  |  | — |  |  |  | 201,579,281 |
Total segment liabilities |  |  | 12,057,539 |  |  |  | — |  |  |  | 12,057,539 |
Operating segment information June 30, 2023 |  | Immunotherapy A$ |  |  | Unallocated A$ |  |  | Consolidated A$ |
Revenue |
License revenue |  |  | — |  |  |  | — |  |  |  | — |
Other income |  |  |  |  |  |  |  |  |  |  |  |
Research material sales |  |  | 191,721 |  |  |  | — |  |  |  | 191,721 |
Grant income |  |  | 3,314,001 |  |  |  | — |  |  |  | 3,314,001 |
Net gain on fair value movement of warrants |  |  | — |  |  |  | 131,896 |  |  |  | 131,896 |
Net gain on foreign exchange |  |  | — |  |  |  | 623,511 |  |  |  | 623,511 |
Interest income |  |  | — |  |  |  | 938,999 |  |  |  | 938,999 |
Total revenue and other income |  |  | 3,505,722 |  |  |  | 1,694,406 |  |  |  | 5,200,128 |
Result |  |  |  |  |  |  |  |  |  |  |  |
Segment Result |  |  | (41,431,305 | ) |  |  | 1,534,957 |  |  |  | (39,896,348 | )
Profit/(loss) before income tax expense |  |  | (41,431,305 | ) |  |  | 1,534,957 |  |  |  | (39,896,348 | )
Income tax expense |  |  | — |  |  |  | — |  |  |  | — |
Loss after income tax expense |  |  |  |  |  |  |  |  |  |  | (39,896,348 | )
Total segment assets |  |  | 147,448,990 |  |  |  | — |  |  |  | 147,448,990 |
Total segment liabilities |  |  | 10,979,601 |  |  |  | — |  |  |  | 10,979,601 |

X
- Definition The disclosure of operating segments. [Refer: Operating segments [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2025-01-01 -Paragraph 23 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_DisclosureOfOperatingSegmentsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | immp_StatementsLineItems
Namespace Prefix: | immp_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration